<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/356c" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/356c/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/356c/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_356c"><akn:num>356c</akn:num><akn:heading>Discontinuance or interruption in the production of life-saving drugs</akn:heading><akn:content><akn:p>§ 356c. Discontinuance or interruption in the production of life-saving drugs(a) In generalA manufacturer of a drug—(1) that is—(A) life-supporting;

(B) life-sustaining; or

(C) intended for use in the prevention or treatment of a debilitating disease or condition, including any such drug used in emergency medical care or during surgery or any such drug that is critical to the public health during a public health emergency declared by the Secretary under section 247d of title 42; and


(2) that is not a radio pharmaceutical drug product or any other product as designated by the Secretary,


shall notify the Secretary, in accordance with subsection (b), of a permanent discontinuance in the manufacture of the drug or an interruption of the manufacture of the drug that is likely to lead to a meaningful disruption in the supply of that drug in the United States, or a permanent discontinuance in the manufacture of an active pharmaceutical ingredient or an interruption in the manufacture of the active pharmaceutical ingredient of such drug that is likely to lead to a meaningful disruption in the supply of the active pharmaceutical ingredient of such drug, and the reasons for such discontinuance or interruption. Notification under this subsection shall include disclosure of reasons for the discontinuation or interruption, and if applicable, an active pharmaceutical ingredient is a reason for, or risk factor in, such discontinuation or interruption, the source of the active pharmaceutical ingredient and any alternative sources for the active pharmaceutical ingredient known by the manufacturer; whether any associated device used for preparation or administration included in the drug is a reason for, or a risk factor in, such discontinuation or interruption; the expected duration of the interruption; and such other information as the Secretary may require.

(b) TimingA notice required under subsection (a) shall be submitted to the Secretary—(1) at least 6 months prior to the</akn:p></akn:content><akn:subsection eId="subsec_356c_a"><akn:num>(a)</akn:num><akn:heading>In general</akn:heading><akn:content><akn:p>(a) In general A manufacturer of a drug— shall notify the Secretary, in accordance with subsection (b), of a permanent discontinuance in the manufacture of the drug or an interruption of the manufacture of the drug that is likely to lead to a meaningful disruption in the supply of that drug in the United States, or a permanent discontinuance in the manufacture of an active pharmaceutical ingredient or an interruption in the manufacture of the active pharmaceutical ingredient of such drug that is likely to lead to a meaningful disruption in the supply of the active pharmaceutical ingredient of such drug, and the reasons for such discontinuance or interruption. Notification under this subsection shall include disclosure of reasons for the discontinuation or interruption, and if applicable, an active pharmaceutical ingredient is a reason for, or risk factor in, such discontinuation or interruption, the source of the active pharmaceutical ingredient and any alternative sources for the acti</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_356c_b"><akn:num>(b)</akn:num><akn:heading>Timing</akn:heading><akn:content><akn:p>(b) Timing A notice required under subsection (a) shall be submitted to the Secretary—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_356c_c"><akn:num>(c)</akn:num><akn:heading>Distribution</akn:heading><akn:content><akn:p>(c) Distribution To the maximum extent practicable, the Secretary shall distribute, through such means as the Secretary deems appropriate, information on the discontinuance or interruption of the manufacture of the drugs described in subsection (a) to appropriate organizations, including physician, health provider, and patient organizations, as described in section 356e of this title.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_356c_d"><akn:num>(d)</akn:num><akn:heading>Confidentiality</akn:heading><akn:content><akn:p>(d) Confidentiality Nothing in this section shall be construed as authorizing the Secretary to disclose any information that is a trade secret or confidential information subject to section 552(b)(4) of title 5 or section 1905 of title 18.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_356c_e"><akn:num>(e)</akn:num><akn:heading>Coordination with Attorney General</akn:heading><akn:content><akn:p>(e) Coordination with Attorney General Not later than 30 days after the receipt of a notification described in subsection (a), the Secretary shall—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_356c_f"><akn:num>(f)</akn:num><akn:heading>Failure to meet requirements</akn:heading><akn:content><akn:p>(f) Failure to meet requirements If a person fails to submit information required under subsection (a) in accordance with subsection (b)—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_356c_g"><akn:num>(g)</akn:num><akn:heading>Expedited inspections and reviews</akn:heading><akn:content><akn:p>(g) Expedited inspections and reviews If, based on notifications described in subsection (a) or any other relevant information, the Secretary concludes that there is, or is likely to be, a drug shortage of a drug described in subsection (a), the Secretary shall, as appropriate—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_356c_h"><akn:num>(h)</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>(h) Definitions For purposes of this section—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_356c_i"><akn:num>(i)</akn:num><akn:heading>Regulations</akn:heading><akn:content><akn:p>(i) Regulations</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_356c_j"><akn:num>(j)</akn:num><akn:heading>Risk management plans</akn:heading><akn:content><akn:p>(j) Risk management plans Each manufacturer of a drug described in subsection (a) or of any active pharmaceutical ingredient or any associated medical device used for preparation or administration included in the drug, shall develop, maintain, and implement, as appropriate, a redundancy risk management plan that identifies and evaluates risks to the supply of the drug, as applicable, for each establishment in which such drug or active pharmaceutical ingredient of such drug is manufactured. A risk management plan under this section shall be subject to inspection and copying by the Secretary pursuant to an inspection or a request under section 374(a)(4) of this title.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>